Key Takeaways

  • Early-stage failure is the default, with 70% to 90% of seed companies dying, making lists of failure risks obvious and unhelpful.
  • BoxGroup abandons consensus votes; an investment moves forward when a single partner develops high conviction in the founder.
  • Partners who skip meeting the founders are formally barred from giving negative feedback or floating market critiques.
  • David Tisch defines seed investing as squinting to see the founder's path to an outlier outcome instead of guarding against losses.
  • This investment discipline is codified as the BoxGroup 'No Grenades' Early-Stage Decision Framework.

The BoxGroup 'No Grenades' Early-Stage Decision Framework

  • 1. Human Champion Ownership (No Voting): A deal only happens if a specific partner genuinely loves it. BoxGroup does not use committee votes or consensus scoring. If one partner has high conviction and commits to the founder, they can execute without winning a firm-wide majority.
  • 2. Time-Invested Requirement for Critique: If you have not spent time meeting with the founders personally, you are barred from giving negative feedback on the deal. Second-hand market opinions from uncommitted partners are disqualified.
  • 3. The 'No Grenades' Rule: Partners are strictly prohibited from tossing rhetorical 'grenades' (broad risk callouts, competitive threats, macro fears) to derail a deal someone else wants to do.
  • 4. Focus on the Outlier Case ('Squinting for Yes'): Do not write memos detailing the 5 obvious reasons a company will fail; 70-90% of early-stage startups fail anyway, making failure analysis trivial. The job is exclusively to identify and align with the founder's vision of how and why the business will achieve massive success.

When This Works (and When It Doesn't)

Tisch applies this rule strictly to seed-stage investing. At that inception point, power-law mechanics govern every return. A single fund-returning outlier pays for dozens of wipeouts, so weeding out failure risks does not generate alpha. As Tisch puts it: “If you name a company at early stage, I can tell you why it's going to fail. Any company. Here are the five risk conditions and here's why it's going to fail. It's the easiest thing to do.” Traditional venture committees fall into cynicism because identifying structural flaws makes investors feel rigorous, even though it kills unconventional ideas.

The framework fails once you move past the seed stage. Growth-stage investing, series B rounds, and capital allocation inside a company require strict downside protection and balance-sheet stress testing. If you are committing tens of millions of dollars to scale unit economics, unvetted optimism will sink you. Late-stage investing demands red teams, forensic diligence, and active critiques. At the seed stage, however, negative analysis simply protects you from striking out while guaranteeing you never hit a home run. “Our job is to say yes to the right things,” Tisch notes, “not to be fearful of saying yes to the ones that don't work.”

What to Do With This

Take this framework into your next high-uncertainty product or hiring meeting. Say your co-founder pitches an unproven user onboarding experiment. Before letting the room pick it apart, enforce Tisch's rules. First, establish that only teammates who observed the actual user research sessions can critique the concept; armchair opinions from uncommitted onlookers are disqualified. Second, ban rhetorical grenades like "what if competitors copy this" or "our current users might get confused." Third, discard consensus voting. If your product lead owns the initiative and believes in the upside, let them ship the experiment. Focus the room on finding what must be true for this experiment to generate a 10x lift, rather than cataloging five obvious risks.